M
MLYS
vs
S&P 500
S&P 500
Over the past 12 months, MLYS has significantly outperformed S&P 500, delivering a return of +193% compared to the S&P 500's +12% growth.
Stocks Performance
MLYS vs S&P 500
Performance Gap
MLYS vs S&P 500
Performance By Year
MLYS vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Mineralys Therapeutics Inc
Glance View
Mineralys Therapeutics, Inc. s a clinical-stage biopharmaceutical company engages in developing medicines to target disease, driven by abnormally elevated aldosterone. The company is headquartered in Radnor, Pennsylvania and currently employs 12 full-time employees. The company went IPO on 2023-02-10. The firm is focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Its product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Company is initially developing for the treatment of patients with uncontrolled hypertension (uHTN). The firm completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uHTN. The company intends to develop lorundrostat for the treatment of chronic kidney disease (CKD).
